Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.
Piatosa
B
B
Child's Health Center, Warsaw, Poland.
Grenda
R
R
Prokurat
S
S
D000293:Adolescent; D015703:Antigens, CD / Q000032:analysis; D017252:CD3 Complex / Q000032:analysis; D002648:Child; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D019084:Fluorescent Antibody Technique, Indirect; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D018655:Lymphocyte Count; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000009:adverse effects*; D013577:Syndrome; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors
D015703:Antigens, CD; D017252:CD3 Complex; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003404:Creatinine